For the Inventor, By the Inventor

Enter assignee name

Gyeonggi-do, South Korea

Daewoong Pharmaceutical Co., Ltd.

USPTO Granted Patents = 77

CIPO Patents = 2

EPO Patents = 56

Trademarks = 7

Forward Citations = 151

Loading Chart...

Loading Chart...

213 inventors (with patents filed for the assignee):

Ji Duck Kim (13 out of 15 patents)

Joon Seok Park (10 out of 46 patents)

In Woo Kim (10 out of 18 patents)

4. Jun Hee Lee (8 out of 62 patents)

5. Sun Ah Jun (7 out of 7 patents)

6. Deok Ki Eom (7 out of 7 patents)

7. Mi Ryeong Han (7 out of 7 patents)

8. Aeri Kim (7 out of 7 patents)

9. Kwan Hyung Cho (7 out of 7 patents)

10. Kyung A Yu (6 out of 6 patents)

11. Youn Jung Yoon (5 out of 5 patents)

12. Min Hee Cho (4 out of 53 patents)

13. Nam Youn Kim (4 out of 4 patents)

14. Jeong-Taek Shin (4 out of 4 patents)

15. Keuk-Chan Bang (4 out of 4 patents)

Core Competencies:

SGLT Inhibitors

Pharmaceutical Compositions

Crystalline Forms

Kinase Inhibitors

Long-Acting Insulin Analogues

Dermal Injection Compositions

Transdermal Delivery Systems

Sodium Channel Blockers

Heterocyclic Compounds

Microsphere Preparation

Film Coated Tablets

Hypertension Treatments

77 patents: Sort by Forward Citations

1. 12497390 - Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same (2025-12-16),

2. 12448360 - Synthesis method for preparing SGLT inhibitor intermediate (2025-10-21),

3. 12447110 - Two-chamber type combined container-syringe (2025-10-21),

4. 12303507 - Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia (2025-05-20),

5. 12227498 - Heterocyclic amine derivative and pharmaceutical composition comprising same (2025-02-18),

6. 12110271 - Manufacturing method for 4-methoxypyrrole derivatives (2024-10-08),

7. 11858894 - Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt (2024-01-02),

8. 11857773 - Syringe safety cap and safety syringe including the same (2024-01-02),

9. 11661406 - Method for producing intermediate useful for synthesis of SGLT inhibitor (2023-05-30),

10. 11655279 - Method for producing active form of long-acting insulin analogue derivative using clostripain (2023-05-23),

11. 11566059 - Long-acting insulin analogues and derivatives thereof (2023-01-31),

12. 11459297 - Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt (2022-10-04),

13. 11433054 - Pharmaceutical preparation and preparation method therefor (2022-09-06),

14. 11407754 - Substituted piperidines as kinase inhibitors (2022-08-09),

15. 11345660 - Method for preparing intermediate of 4-methoxypyrrole derivative (2022-05-31),

Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company. Established in 1945, Daewoong has dedicated itself to researching and developing innovative medical solutions. With a strong focus on the global market, Daewoong aims to improve the health and well-being of people around the world. The company's portfolio includes various therapeutic areas such as central nervous system disorders, cardiovascular diseases, and immunology. Daewoong strives to become a global leader in the pharmaceutical industry through continuous innovation and investment in R&D.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

77 Patents

#19 in Gyeonggi-do

#226 in South Korea

#9,511 in the World

Gyeonggi-do, South Korea

Daewoong Pharmaceutical Co., Ltd.

Forward Citations = 151

213 inventors:

Ji Duck Kim (13 out of 15 patents)

Joon Seok Park (10 out of 46 patents)

In Woo Kim (10 out of 18 patents)

4. Jun Hee Lee (8 out of 62 patents)

5. Sun Ah Jun (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…